HomeProductsBioactive CompoundsCell CycleCDKTrilaciclib
Chemical structure of CAS 1374743-00-6

Trilaciclib

CAS No.1374743-00-6
MDL No.MFCD30747890
MFC24H30N8O
MW446.50
InChI KeyPDGKHKMBHVFCMG-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Trilaciclib is a piperazine and a pyridine derivative.

CAS No.1374743-00-6
Product NameTrilaciclib

Biological Targets

CDK4·CDK6

Associated Conditions

small cell lung carcinoma·breast neoplasm·urinary bladder cancer·osteosarcoma·lung cancer·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.

Science translational medicine • Vol. 9, Issue 387 • 2017
PMID: 28446688PMC: PMC5774632DOI: 10.1126/scitranslmed.aal3986

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.

Molecular cancer therapeutics • Vol. 15, Issue 5 • 2016
PMID: 26826116DOI: 10.1158/1535-7163.MCT-15-0775

Identification and blockade of vascular H2 receptors.

Federation proceedings • Vol. 35, Issue 8 • 1976
PMID: 5314

Documentation

Similar Products